릭스테 바이오테크놀로지 홀딩스(LIXT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.05 (+3.05%), 시가총액 $0.06B, 52주 범위 $0.71 ~ $6.01.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for
릭스테 바이오테크놀로지 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
릭스테 바이오테크놀로지 홀딩스의 현재 주가는 $4.05 (+3.05%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
릭스테 바이오테크놀로지 홀딩스의 시가총액은 약 $0.06B입니다.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing